Mostrando 2 resultados de: 2
In vitro and in vivo preclinical venom inhibition assays identify metalloproteinase inhibiting drugs as potential future treatments for snakebite envenoming by Dispholidus typus
ArticleAbstract: Snakebite envenoming affects more than 250,000 people annually in sub-Saharan Africa. Envenoming byPalabras claves:Boomslang, drugs, Small molecules, snakebite, SVMPAutores:Alsolaiss J., Casewell N.R., Clare R.H., Crittenden E., Edge R.J., Hall S.R., Harrison R.A., Kool J., Marriott A.E., Stefanie K. Menzies, Westhorpe A., Xie C.Fuentes:scopusTwo snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing
ArticleAbstract: Background Snakebite is a major public health concern in Eswatini, where treatment relies upon one aPalabras claves:Autores:Alsolaiss J., Casewell N.R., Crittenden E., Edge R.J., Hall S.R., Harrison R.A., Lalloo D.G., Litschka-Koen T., Murray J., Padidar S., Pons J., Shongwe N., Stefanie K. Menzies, Thomas B., Westhorpe A.Fuentes:scopus